Clarus Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Clarus Therapeutics sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Clarus Therapeutics: 11 sponsored US clinical trials, none currently recruiting.

Clarus Therapeutics sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 4 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Male Hypogonadism, with 2 trials.

Top-decile sponsor footprint

Clarus Therapeutics ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED Phase 1

Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes

NCT03973840
COMPLETED Phase 2

The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate

NCT02921386
COMPLETED Phase 3

A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

NCT02722278
COMPLETED Phase 1

Phlebotomy Study of Testosterone Undecanoate

NCT02670343
COMPLETED Phase 3

Safety and Efficacy Trial of Testosterone Undecanoate

NCT01765179
COMPLETED Phase 3

Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men

NCT01699178
COMPLETED Phase 3

Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

NCT01403116
COMPLETED Phase 2

Pharmacokinetic Study to Determine Time to Steady-state

NCT00911586
COMPLETED Phase 2

Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation

NCT00924612
COMPLETED Phase 2

Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men

NCT00695110
COMPLETED Phase 2

Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men

NCT02697188

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 4

Therapeutic Areas

Male Hypogonadism 2
Primary Hypogonadism 1
Secondary Hypogonadism 1
Hypogonadism 1
Hypogonadism, Male 1

How the Clarus Therapeutics early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).

Phase mix: 4 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Male Hypogonadism (2 trials), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Clarus Therapeutics: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Clarus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Clarus TherapeuticsAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Clarus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Clarus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Clarus Therapeutics page

11 registered trials is a research-attention snapshot, not an endorsement of Clarus Therapeutics or any single study.

  • None of Clarus Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Male Hypogonadism is the condition Clarus Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Male Hypogonadism trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Clarus Therapeutics pipeline card: 11 registered trials from official public datasets.Report a data error.